Argentina is second market to wave through Eli Lilly’s Verzenio

Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) this week cleared Eli Lilly’s breast cancer treatment Verzenio (abemaciclib) for marketing, as GBI analysis reveals. The orally administered therapy is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation in estrogen receptor-positive (ER+) breast cancer cells. Verzenio is a protein kinase inhibitor that selectively acts on CDK4 and CDK6, thus preventing Rb phosphorylation and stalling the cell cycle, which results in tumor cell senescence and apoptosis.

GBI analysis reveals that ANMAT’s approval is the second for Verzenio in Latin America after the drug obtained market clearance earlier this year in Brazil, where it is commercialized under the brand name Verzenios, as GBI reported. As is the case in Brazil, Verzenio will compete in the Argentina market with Pfizer’s CDK4/CDK6 inhibitor Ibrance (palbociclib), which was launched in the country in 2016, according to GBI SOURCE.


Related news
China's National Medical Products Administration (NMPA) released the 22nd batch of reference drugs for generic quality consistency evaluation (GQCE) work.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) is set to initiate a first-in-human trial in Australia for pipeline candidate CS3002, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), after receiving ethics approval from the Human Research Ethics Committee in Australia and filing an electronic Clinical Trial Notification with the Therapeutic Goods Administration (TGA).
  • 1566528937246
  • China
  • Drug
GBI analysis reveals that Colombia’s National Food and Drug Surveillance Institute (INVIMA) this week gave marketing clearance to Pfizer’s Trazimera (trastuzumab-qyyp), a biosimilar version of Roche’s oncology treatment Herceptin.
GBI analysis reveals that Pfizer last week obtained marketing clearance from Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) for its breast cancer therapy Talzenna (talazoparib).
US-based major Eli Lilly & Co., (NYSE.LLY) reported Q2’19 financials, with global growth up 3% year-on-year (YOY) in constant exchange rate (CER) terms to USD 5.637 billion. Lilly enjoyed strong China market growth of 26% YOY at CER during the quarter, according to CFO Josh Smiley speaking during the firm’s Q2’19 earnings conference call.
Recent news
Colombia’s Ministry of Commerce, Industry and Tourism (MINCIT), Business Growth Management Unit (INNPULSA), and Spain’s Centre for the Development of Industrial Technology (CDTI), have launched a financing program for joint biotechnology projects between companies of both countries in industries including the pharmaceutical and chemical sectors.
China-based Sichuan Kelun Pharmaceutical Co., Ltd (002422.SZ) announced clinical trial (CT) approval from the National Medical Products Administration (NMPA) in relation to its KL-A293, a novel immunotherapy co-developed by its subsidiaries Kelun-Biotech Biopharmaceutical Co., Ltd and Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd (GBI translation).
China-based Shandong Buchang Pharmaceuticals Co., Ltd (603858.SH) is set to bulk up compatriot firm Shanghai Hepu Medical Technology Co., Ltd (GBI translation) with RMB 143 million, equating to a 71.7% stake in the latter upon transaction closure.
  • 1568604289219
  • China
  • Deals
Shanghai Henlius Pharmaceutical Co., Ltd, the biotech arm of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd, (SHA: 600196; HKG: 02196), announced the out-licensing deal with Indonesia-headquartered PT Kalbe Farma, Tbk.’s subsidiary PT Kalbe Genexine Biologics (KG Bio).
GBI analysis reveals that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week details of a recent approval for local laboratory Asofarma’s Alzheimer patch Remizeral (rivastigmine), a first generic entrant of Novartis’s Exelon.
According to GBI analysis, Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week released its approval of local laboratory Tuteur’s Zanterib (cabozantinib), a generic version of Ipsen’s Exelixis-licensed oncology therapy Cabometyx.
GBI analysis shows that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week approved domestic Laboratorio Varifarma’s Ponatib (ponatinib), as first-mover generic version of Austria-based Pint Pharma’s cancer drug Iclusig.
Analytics Snapshot

Analytics Snapshot